Brief: PDS Biotechnology Announces Achievement Of Efficacy Threshold In Stage 2 Of Versatile-002 Trial Evaluating Pds0101 And Keytruda® In Head, Neck Cancer

PDS Biotechnology

14/06/2023 11:09

June 14 (Reuters) - PDS Biotechnology Corp  PDSB.O :
    * PDS BIOTECHNOLOGY ANNOUNCES ACHIEVEMENT OF EFFICACY
THRESHOLD IN
STAGE 2 OF VERSATILE-002 TRIAL EVALUATING PDS0101 AND KEYTRUDA®
IN HEAD, NECK CANCER
    * PDS BIOTECHNOLOGY CORP - EFFICACY AND SAFETY CONTINUE TO
BE
MONITORED AS ADDITIONAL PATIENTS HAVE YET TO UNDERGO IMAGING
EVALUATION
    * PDS BIOTECHNOLOGY - PLANS TO INITIATE VERSATILE-003 AS
RESULT OF
SUCCESSFUL COMPLETION OF END-OF-PHASE 2 MEETING IN Q3 2022 WITH
FDA
    * PDS BIOTECHNOLOGY - IN PREPARATION FOR VERSATILE-003
TRIAL, CO
PLANS TO SUBMIT AMENDED INVESTIGATIONAL NEW DRUG APPLICATION TO
FDA IN Q3 2023

Source text for Eikon:  ID: 
Further company coverage:  PDSB.O